Zydus Lifesciences Limited (BOM:532321)
India · Delayed Price · Currency is INR 1,084.35
+13.45 (1.26%)
At close: Jun 22, 2026
Zydus Lifesciences Stock Forecast
Stock Price Forecast
According to 30 analysts polled by S&P Global, Zydus Lifesciences stock has a consensus rating of "Hold" and an average price target of ₹1,067. The average 1-year stock price forecast is 1.65% lower than the current stock price, while the lowest is ₹800.00 (-26.22%) and the highest is ₹1,457 (+34.37%).
Price Target: ₹1,067 (-1.65%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Zydus Lifesciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 5 | 4 | 6 | 6 |
| Buy | 8 | 8 | 8 | 8 | 9 | 9 |
| Hold | 10 | 9 | 10 | 10 | 10 | 10 |
| Sell | 4 | 4 | 4 | 4 | 2 | 2 |
| Strong Sell | 3 | 3 | 3 | 3 | 3 | 3 |
| Total | 30 | 30 | 30 | 29 | 30 | 30 |
Financial Forecast
Revenue This Year
309.95B
from 271.48B
Increased by 14.17%
Revenue Next Year
334.47B
from 309.95B
Increased by 7.91%
EPS This Year
41.19
from 54.00
Decreased by -23.73%
EPS Next Year
46.66
from 41.19
Increased by 13.29%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 343.2B | ||
| Avg | 310.0B | ||
| Low | 297.5B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 26.4% | ||
| Avg | 14.2% | ||
| Low | 9.6% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 46.40 | ||
| Avg | 41.19 | ||
| Low | 35.30 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | -14.1% | ||
| Avg | -23.7% | ||
| Low | -34.6% |